Shots:
- Variational AI has entered into a collaboration with Merck to design and optimize novel small molecule candidates against two undisclosed targets using Variational AI’s Enki platform
- As per the deal, Variational AI will leverage its fine-tuned Enki platform trained on Merck’s proprietary data to generate & optimize small-molecule candidates for Merck’s targets, with Merck holding exclusive development & commercialization rights in exchange for ~$349M in upfront & milestone payments
- Enki platform is built on internal, curated public data & proprietary generative models to design & optimize small-molecule leads aligned with partner target product profiles
Ref: Variational AI | Image: Variational AI and Merck| Press Release
Related News:- Angelini Pharma Enters an Exclusive Option Agreement with Sovargen to Develop and Commercialize SVG105 for Brain Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
